KR101330626B1 - 탈아미드화된 인터페론-베타 - Google Patents

탈아미드화된 인터페론-베타 Download PDF

Info

Publication number
KR101330626B1
KR101330626B1 KR1020077011869A KR20077011869A KR101330626B1 KR 101330626 B1 KR101330626 B1 KR 101330626B1 KR 1020077011869 A KR1020077011869 A KR 1020077011869A KR 20077011869 A KR20077011869 A KR 20077011869A KR 101330626 B1 KR101330626 B1 KR 101330626B1
Authority
KR
South Korea
Prior art keywords
protein
ifn
interferon
deamidated
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077011869A
Other languages
English (en)
Korean (ko)
Other versions
KR20070084559A (ko
Inventor
겐지 후루야
드보라 존슨-잭슨
다이애나 티에라 루시오
Original Assignee
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 filed Critical 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드
Publication of KR20070084559A publication Critical patent/KR20070084559A/ko
Application granted granted Critical
Publication of KR101330626B1 publication Critical patent/KR101330626B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020077011869A 2004-11-10 2005-11-10 탈아미드화된 인터페론-베타 Expired - Fee Related KR101330626B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62683704P 2004-11-10 2004-11-10
US60/626,837 2004-11-10
PCT/US2005/040758 WO2006053134A2 (en) 2004-11-10 2005-11-10 Deamidated interferon-beta

Publications (2)

Publication Number Publication Date
KR20070084559A KR20070084559A (ko) 2007-08-24
KR101330626B1 true KR101330626B1 (ko) 2013-11-18

Family

ID=36337216

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011869A Expired - Fee Related KR101330626B1 (ko) 2004-11-10 2005-11-10 탈아미드화된 인터페론-베타

Country Status (16)

Country Link
US (2) US7595040B2 (https=)
EP (1) EP1809662B1 (https=)
JP (1) JP4891250B2 (https=)
KR (1) KR101330626B1 (https=)
CN (1) CN101056890B (https=)
AT (1) ATE415421T1 (https=)
AU (1) AU2005304486B2 (https=)
BR (1) BRPI0517697A (https=)
CA (1) CA2587061C (https=)
DE (1) DE602005011321D1 (https=)
ES (1) ES2318575T3 (https=)
MX (1) MX2007004990A (https=)
PL (1) PL1809662T3 (https=)
PT (1) PT1809662E (https=)
RU (1) RU2404190C2 (https=)
WO (1) WO2006053134A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
WO2008020968A2 (en) * 2006-08-08 2008-02-21 Novartis Ag Recombinant interferon-beta with enhanced biological activity
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
ES2736503T3 (es) * 2014-04-04 2020-01-02 Ares Trading Sa Nuevos análogos de la proteína IFN beta
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087753A1 (en) 2003-03-31 2004-10-14 Samsung Fine Chemicals Co., Ltd. Mutein of human interferon-beta and its preparation method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP4878664B2 (ja) 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
CA2304808C (en) * 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
ES2355055T3 (es) 1999-07-28 2011-03-22 Genentech, Inc. Composiciones y procedimientos para el tratamiento de tumores.
ES2180416B1 (es) 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
RU2216345C1 (ru) * 2002-03-21 2003-11-20 Закрытое Акционерное Общество "Биокад" Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087753A1 (en) 2003-03-31 2004-10-14 Samsung Fine Chemicals Co., Ltd. Mutein of human interferon-beta and its preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BBRC Vol.312:1082-1086 (2003) *

Also Published As

Publication number Publication date
RU2404190C2 (ru) 2010-11-20
ATE415421T1 (de) 2008-12-15
US7595040B2 (en) 2009-09-29
WO2006053134A3 (en) 2006-08-31
RU2007121515A (ru) 2008-12-20
EP1809662B1 (en) 2008-11-26
ES2318575T3 (es) 2009-05-01
EP1809662A2 (en) 2007-07-25
WO2006053134A2 (en) 2006-05-18
BRPI0517697A (pt) 2008-10-14
PT1809662E (pt) 2009-02-26
MX2007004990A (es) 2007-06-14
PL1809662T3 (pl) 2009-07-31
JP2008519769A (ja) 2008-06-12
JP4891250B2 (ja) 2012-03-07
CA2587061A1 (en) 2006-05-18
CA2587061C (en) 2011-08-16
AU2005304486A1 (en) 2006-05-18
AU2005304486B2 (en) 2011-08-11
CN101056890A (zh) 2007-10-17
DE602005011321D1 (de) 2009-01-08
US20090263355A1 (en) 2009-10-22
KR20070084559A (ko) 2007-08-24
US20060120998A1 (en) 2006-06-08
CN101056890B (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
KR0184235B1 (ko) 거핵구 형성 인자
May et al. Phosphorylation of secreted forms of human β2-interferon/hepatocyte stimulating factor/interleukin-6
Kwak et al. Intracellular interleukin (IL)-1 family cytokine processing enzyme
Chiesa et al. The phosphorylation sites of the B2 chain of bovine α-crystallin
KR20040052481A (ko) 재조합 단백질의 수득률을 증가시키는 방법
AU5164590A (en) Use of il-7 in providing medications for stimulation of platelet production
US20090263355A1 (en) Deamidated interferon-beta
DE69805844T2 (de) Ifnnar/ifn komplex
KR20090047452A (ko) 생물학적 활성이 증강된 재조합 인터페론-베타
US20030017550A1 (en) DNA sequences encoding fusion proteins comprising IFN-beta and TM-alpha1
Lin et al. Interferon-β-1b (Betaseron®): A model for hydrophobic therapeutic proteins
CA2219275C (en) Therapeutic agent and treatment for canine intractable dermatitis
EP0796276B1 (en) Gradual modification, super-agonists and antagonists of signal-proteins and peptides
US20020173475A1 (en) Methods to inhibit viral replication
CA2256368A1 (en) An interleukin-5 antagonist
AU2004262637A1 (en) Method for producing a polypeptide
STEBBING PROTEINS AS THERAPEUTICS
Lin et al. and Maninder S. Hora
CA2528964A1 (en) Interferon variants with improved properties

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20161113

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20161113

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000